基线疾病活动度指标可预测结构损伤进展:AMPLE与AVERT试验事后分析
该事后分析基于AMPLE和AVERT两项随机双盲III期试验,评估RAPID3、DAS28(CRP)、M-DAS28(CRP)及SDAI/CDAI对RA结构损伤进展的预测能力。基线RAPID3、DAS28(CRP)和M-DAS28(CRP)显著预测结构进展,且优于SDAI和CDAI。
要点
- 基线RAPID3、DAS28(CRP)、M-DAS28(CRP)可预测RA结构损伤进展。
- 上述指标预测能力优于SDAI和CDAI。
- 结论来自AMPLE和AVERT试验的事后分析。
核心结论
- 在两项RA患者人群的事后分析中,RAPID3、DAS28(CRP)和M-DAS28(CRP)能较好地预测结构损伤进展。
研究设计与样本
- 事后分析纳入AMPLE试验全部随机治疗患者(N=646)及AVERT试验接受阿巴西普联合MTX或MTX单药治疗的患者(N=235)。
- 采用校正logistic回归分析基线疾病活动度与结构损伤进展的关系,并计算ROC曲线下面积。
主要发现
- 基线RAPID3、DAS28(CRP)和M-DAS28(CRP)评分显著预测AMPLE第12和24个月的结构进展(P<0.05)。
- 基线RAPID3、DAS28(CRP)和M-DAS28(CRP)评分显著预测AVERT第6和12个月的结构进展(P<0.01)。
- 上述指标的预测能力强于SDAI和CDAI。
关键数值与推荐
- 结构损伤进展定义为较基线变化大于最小可检测变化。
临床怎么用
- 在RA临床评估中,可优先采用RAPID3、DAS28(CRP)或M-DAS28(CRP)评估基线疾病活动度以辅助预判结构损伤进展风险。
局限性
- 本研究为事后分析,结果需在更广泛人群中验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Data from two double-blind, randomized, Phase III studies were analysed to investigate the ability of Routine Assessment of Patient Index Data 3, DAS28 (CRP), modified (M)-DAS28 (CRP) and Simplified or Clinical Disease Activity Indices to predict structural damage progression in RA. METHODS: This post hoc analysis included data from the 2-year Abatacept vs adaliMumab comParison in bioLogic-naïvE RA subjects with background MTX (AMPLE) trial in biologic-naïve patients with active RA (<5 years) and an inadequate response to MTX, and the 12-month treatment period of the Assessing Very Early Rheumatoid arthritis Treatment (AVERT) trial in MTX-naïve patients with early RA (⩽2 years) and poor prognostic indicators. Adjusted logistic regression analysis assessed the relationship between baseline disease activity and structural damage progression (defined as change from baseline greater than the smallest detectable change) at 12 and 24 months in AMPLE and 6 and 12 months in AVERT. Areas under the receiver operating characteristic curves for the impact of baseline disease activity on structural damage progression were calculated. RESULTS: Adjusted logistic regression analyses included all randomized and treated patients in AMPLE (N = 646) and those who received abatacept plus MTX or MTX monotherapy in AVERT (N = 235). Baseline Routine Assessment of Patient Index Data 3, DAS28 (CRP) and M-DAS28 (CRP) scores significantly predicted structural progression at months 12 and 24 in AMPLE (P < 0.05) and months 6 and 12 in AVERT (P < 0.01), and were stronger predictors than Simplified or Clinical Disease Activity Indices. CONCLUSION: In this post hoc analysis of two patient populations with RA, Routine Assessment of Patient Index Data 3, DAS28 (CRP) and M-DAS28 (CRP) were good at predicting structural damage. TRIAL REGISTRATION: ClinicalTrials.gov, http://clinicaltrials.gov: NCT00929864 (AMPLE); NCT01142726 (AVERT).
引用
- Keystone EC, Ahmad HA, Yazici Y, et al. Disease activity measures at baseline predict structural damage progression: data from the randomized, controlled AMPLE and AVERT trials. Rheumatology (Oxford). 2020. PMID: 31819995. doi:10.1093/rheumatology/kez455
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。